Global Opioid Induced Constipation Drug Market – Industry Analysis and Forecast (2018-2026)
Global Opioid Induced Constipation Drug Market was valued at US$ 2.1Bn in 2017 and is expected to reach US$ 3.2Bn by 2026 at a CAGR of 5.4%.
The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the global opioid induced constipation drug market dynamics, structure by identifying and analysing the market segments and project the global market size.
Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global opioid induced constipation drug market.
Request For Free Sample Report : https://www.maximizemarketresearch.com/request-sample/25516
The number of patients suffering from opioid induced constipation is growing across the globe. Close to 100 mn U.S. patients in 2013 were suffering from opioid induced constipation, according to the American Academy of Pain Medicine. They added that this number is anticipated to increase as the number of people consuming opioid drugs increases. With an increasing awareness of the commercial availability of a large type of opioid drugs, people have resorted to using them for longer terms to treat chronic pains.
Increasing incidences of diseases associated with old age, impaired body functions, and rise in the use of medicines such as antidepressants and anticholinergic have collectively led to a high prevalence of constipation among the elderly population. This drives growth in the opioid induced constipation market globally. The use of laxatives for opioid induced constipation is a major challenge that is reducing sales of approved drugs meant for the treatment of opioid induced constipation.
Lubiprostone segment is leading the global opioid induced constipation drug market. Lubiprostone under the brand name Amitiza is indicated for treating opioid induced constipation drug, where it major indication is for chronic idiopathic constipation (CIC). Lubiprostone is projected that the segment will take over the market share of methylnaltrexone bromide. Moreover, naloxegol is expected to grow at highest CAGR over the forecast period. The drug is under testing for many patient types such as pregnant women and patients less than 17 years of age. So, future approvals are expected to lead the market.
Region-wise, North America is the dominant regional opioid induced constipation drugs market through the forecast period. Early bird approval of opioid induced constipation drugs by the USFDA and high consumption of opioids in the US is the prime growth factors for the opioid induced constipation drugs market in North America. Besides, Germany, UK, and Spain are the major countries setting the market dynamics in Europe. Overall, the developed countries across the world, predominantly North America and Europe are the key consumers of opioid induced constipation drugs.
Do Inquiry Before Purchasing Report Here: https://www.maximizemarketresearch.com/inquiry-before-buying/25516
Scope of Global Opioid Induced Constipation Drug Market
Global Opioid Induced Constipation Drug Market, by Drug type
• Methylnaltrexone Bromide
• Lubiprostone
• Naloxegol
• Naldemedine
• Docusate Sodium
• Others
Global Opioid Induced Constipation Drug Market, by Prescription type
• Prescribed
• Over The Counter
Global Opioid Induced Constipation Drug Market, by Region
• North America
• Europe
• Asia Pacific
• Middle East and Africa
• South America
Key players operating in Global Opioid Induced Constipation Drug Market
• GlaxoSmithKline, Inc.
• AstraZeneca plc, Inc.
• Pfizer, Inc.
• S.L.A. Pharma AG
• AIKO Biotechnology
• Cubist Pharmaceuticals
• Salix Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
Browse Full Report with Facts and Figures of Opioid Induced Constipation Drug Market Report at: https://www.maximizemarketresearch.com/market-report/global-opioid-induced-constipation-drug-market/25516/
MAJOR TOC OF THE REPORT
Chapter One: Opioid Induced Constipation Drug Market Overview
Chapter Two: Manufacturers Profiles
Chapter Three: Global Opioid Induced Constipation Drug Market Competition, by Players
Chapter Four: Global Opioid Induced Constipation Drug Market Size by Regions
Chapter Five: North America Opioid Induced Constipation Drug Revenue by Countries
Chapter Six: Europe Opioid Induced Constipation Drug Revenue by Countries
Chapter Seven: Asia-Pacific Opioid Induced Constipation Drug Revenue by Countries
Chapter Eight: South America Opioid Induced Constipation Drug Revenue by Countries
Chapter Nine: Middle East and Africa Revenue Opioid Induced Constipation Drug by Countries
Chapter Ten: Global Opioid Induced Constipation Drug Market Segment by Type
Chapter Eleven: Global Opioid Induced Constipation Drug Market Segment by Application
Chapter Twelve: Global Opioid Induced Constipation Drug Market Size Forecast (2019-2026)
About Us:
Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Contact info:
Name: Lumawant Godage
Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.
Email: [email protected]
Contact:+ 919607065656/ +919607195908
Website: www.maximizemarketresearch.com
